These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24815725)

  • 1. Test-retest reliability of a continuous glucose monitoring system in individuals with type 2 diabetes.
    Terada T; Loehr S; Guigard E; McCargar LJ; Bell GJ; Senior P; Boulé NG
    Diabetes Technol Ther; 2014 Aug; 16(8):491-8. PubMed ID: 24815725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of CGM-Derived Measures of Glycemic Variability Between Pancreatogenic Diabetes and Type 2 Diabetes Mellitus.
    Shivaprasad C; Aiswarya Y; Kejal S; Sridevi A; Anupam B; Ramdas B; Gautham K; Aarudhra P
    J Diabetes Sci Technol; 2021 Jan; 15(1):134-140. PubMed ID: 31282179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus.
    Kim MJ; Jung HS; Hwang-Bo Y; Cho SW; Jang HC; Kim SY; Park KS
    Acta Diabetol; 2013 Aug; 50(4):505-10. PubMed ID: 21688018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control.
    Rodbard D
    Diabetes Technol Ther; 2009 Jun; 11 Suppl 1():S55-67. PubMed ID: 19469679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of glycemic variability in well-controlled type 2 diabetes mellitus.
    Chon S; Lee YJ; Fraterrigo G; Pozzilli P; Choi MC; Kwon MK; Chin SO; Rhee SY; Oh S; Kim YS; Woo JT
    Diabetes Technol Ther; 2013 Jun; 15(6):455-60. PubMed ID: 23617251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased glycemic variability and decrease of the postprandial glucose contribution to HbA1c in obese subjects across the glycemic continuum from normal glycemia to first time diagnosed diabetes.
    Fysekidis M; Cosson E; Banu I; Duteil R; Cyrille C; Valensi P
    Metabolism; 2014 Dec; 63(12):1553-61. PubMed ID: 25308444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: an analysis of 480 subjects.
    Jin SM; Kim TH; Bae JC; Hur KY; Lee MS; Lee MK; Kim JH
    Diabetes Res Clin Pract; 2014 May; 104(2):266-72. PubMed ID: 24630619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report.
    Matsutani D; Sakamoto M; Iuchi H; Minato S; Suzuki H; Kayama Y; Takeda N; Horiuchi R; Utsunomiya K
    Cardiovasc Diabetol; 2018 Mar; 17(1):36. PubMed ID: 29514695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CGMS and Glycemic Variability, Relevance in Clinical Research to Evaluate Interventions in T2D, a Literature Review.
    Breyton AE; Lambert-Porcheron S; Laville M; Vinoy S; Nazare JA
    Front Endocrinol (Lausanne); 2021; 12():666008. PubMed ID: 34566883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of a computer program to calculate the mean amplitude of glycemic excursions.
    Fritzsche G; Kohnert KD; Heinke P; Vogt L; Salzsieder E
    Diabetes Technol Ther; 2011 Mar; 13(3):319-25. PubMed ID: 21291337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups.
    Hill NR; Oliver NS; Choudhary P; Levy JC; Hindmarsh P; Matthews DR
    Diabetes Technol Ther; 2011 Sep; 13(9):921-8. PubMed ID: 21714681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients.
    Sun J; Dou JT; Wang XL; Yang GQ; Lü ZH; Zheng H; Ma FL; Lu JM; Mu YM
    Chin Med J (Engl); 2011 Nov; 124(22):3641-5. PubMed ID: 22340217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetes.
    Ohara M; Nagaike H; Goto S; Fukase A; Tanabe Y; Tomoyasu M; Yamamoto T; Hayashi T; Fukui T; Hirano T
    Diabetes Res Clin Pract; 2018 May; 139():253-261. PubMed ID: 29501829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships among different glycemic variability indices obtained by continuous glucose monitoring.
    Saisho Y; Tanaka C; Tanaka K; Roberts R; Abe T; Tanaka M; Meguro S; Irie J; Kawai T; Itoh H
    Prim Care Diabetes; 2015 Aug; 9(4):290-6. PubMed ID: 25456706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternate glycemic markers reflect glycemic variability in continuous glucose monitoring in youth with prediabetes and type 2 diabetes.
    Chan CL; Pyle L; Kelsey MM; Newnes L; Baumgartner A; Zeitler PS; Nadeau KJ
    Pediatr Diabetes; 2017 Nov; 18(7):629-636. PubMed ID: 27873436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The reference values of glycemic parameters for continuous glucose monitoring and its clinical application].
    Zhou J; Jia WP; Yu M; Yu HY; Bao YQ; Ma XJ; Lu W; Hu C; Xiang KS
    Zhonghua Nei Ke Za Zhi; 2007 Mar; 46(3):189-92. PubMed ID: 17547797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose Variability Assessed with Continuous Glucose Monitoring: Reliability, Reference Values, and Correlations with Established Glycemic Indices-The Maastricht Study.
    Foreman YD; Brouwers MCGJ; van der Kallen CJH; Pagen DME; van Greevenbroek MMJ; Henry RMA; Koster A; Wesselius A; Schaper NC; Stehouwer CDA
    Diabetes Technol Ther; 2020 May; 22(5):395-403. PubMed ID: 31886732
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring.
    Abrahamian H; Francesconi M; Loiskandl A; Dzien A; Prager R; Weitgasser R
    Diabetes Technol Ther; 2004 Feb; 6(1):31-7. PubMed ID: 15000767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.